Literature DB >> 788749

A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.

M J West, M J Kendall, M Mitchard, E B Faragher.   

Abstract

1 Plasma concentrations of oxprenolol have been compared in six healthy volunteers after 80 and 160 mg doses of a new slow release (SR) oxprenolol preparation, after an 80 ng dose of conventional oxprenolol (CO), and after the second of two 80 mg doses of conventional oxprenolol given 12 h apart. Basal pulse rates and blood pressures, and pulse rates before and after a standard exercise test have been compared after the four active treatments and after a placebo. 2 Peak plasma concentrations of oxprenolol attained after 160 mg of the slow release preparation were similar to the peak concentrations after the single 80 mg dose of conventional oxprenolol. Higher concentrations, however, persisted for much longer after the slow release preparations than after the conventional preparations. 3 Neither oxprenolol formulation had any effect on resting pulse rate or blood pressure in normotensive volunteers. 4 Comparison with placebo showed that the single dose of the conventional oxprenolol produced a significant reduction in exercise induced tachycardia for 8 h whereas the high dose of the slow release preparation produced a similar reduction which lasted for at least 14 hours.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788749      PMCID: PMC2958765          DOI: 10.1111/j.1365-2125.1976.tb00619.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  The two-step exercise electrocardiogram: a test for coronary insufficiency.

Authors:  A M MASTER
Journal:  Ann Intern Med       Date:  1950-05       Impact factor: 25.391

3.  To be taken as directed.

Authors:  M S Gatley
Journal:  J R Coll Gen Pract       Date:  1968-07

4.  Prediction of systemic availability from plasma-level data after oral drug administration.

Authors:  D Perrier; M Gibaldi; R N Boyes
Journal:  J Pharm Pharmacol       Date:  1973-03       Impact factor: 3.765

5.  Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.

Authors:  C G Regårdh; K O Borg; R Johansson; G Johnsson; L Palmer
Journal:  J Pharmacokinet Biopharm       Date:  1974-08

6.  Different effects of adrenergic beta-receptor blockade on heart rate response to mental stress, catecholamines, and exercise.

Authors:  S H Taylor; M K Meeran
Journal:  Br Med J       Date:  1973-11-03

7.  Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man.

Authors:  L Brunner; P Imhof; D Jack
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

  7 in total
  17 in total

1.  Effects of inflammatory disease on plasma oxprenolol concentrations.

Authors:  M J Kendall; C P Quarterman; H Bishop; R E Schneider
Journal:  Br Med J       Date:  1979-08-25

2.  Bioavailability of beta-adrenoceptor blocking drugs.

Authors:  G Johnsson; C G Regardh
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

3.  Exercise responses of healthy subjects in the evaluation of cardioselectivity of beta-blockers.

Authors:  K L Woods; S P Linton; M J Kendall; E B Faragher; R J Grieve
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

4.  Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.

Authors:  C P Quaterman; M J Kendall; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

5.  Can once daily dosage be effective in the treatment of hypertension throughout 24 hours? A controlled evaluation of sustained release oxprenolol.

Authors:  G N Volan; H J Rogers; F House
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

6.  Bioavailability of conventional and slow-release oxprenolol in fasted and nonfasted individuals.

Authors:  C P Dawes; M J Kendall; P G Welling
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

7.  A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.

Authors:  M J Kendall; V A John; C P Quarterman; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

8.  Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

9.  Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension.

Authors:  R G Wilcox; J R Hampton
Journal:  Br Heart J       Date:  1981-11

10.  Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris.

Authors:  M J Bowles; N S Khurmi; M J O'Hara; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.